Boyalife’ Chairman Dr. Chris Xu Attend 2019 SAPA Healthcare Investment Forum & Roadshow
Dr. Chris Xu, the chairman of Boyalife Group, was invited to fireside chat at the 2019 SAPA Healthcare Investment Forum & [...]
CAR-TXpress™ is Concerned by Academic Journal
Recently, ThermoGenesis’s automated, functionally-closed CAR-TXpress™ platform has received attention form international academic journal ‘Biotechnology Advances’. In the paper, titled ‘Standardizing [...]
Driving CAR-T Manufacture Optimization through Technology Innovation
Philip H Coelho, Founder and Chief Technology Officer (CTO) of ThermoGenesis Corp., the device Division of Cesca Therapeutics is an [...]
Boyalife to Expand its CDMO Services into the Asia Pacific Region
On March 14, 2018, ThermoGenesis, the device subsidiary of Cesca Therapeutics (Nasdaq: KOOL), signed a license agreement with IncoCell Tianjin Ltd., [...]
Boyalife: Always Be a Practitioner of Public Responsibility
Environmental protection, ecological construction, energy conservation and emissions reduction have become the inevitable issues for future economic and social development, [...]
Boyalife Attends Advanced Cell Therapy Shanghai Summit 2017 to Promote the Sustainable Development of the Global Biomanufacturing Industry
November 17, 2017 saw the opening of the Advanced Cell Therapy Shanghai Summit 2017 (ACTSS2017), which was held at Grand [...]
Fujita Health University and Boyalife Group Partner to Build International Regenerative Medicine Research Center in Japan
On November 11, 2017, a delegation from Fujita Health University (FHU) visited Boyalife Group to sign a formal cooperation agreement to jointly [...]
Xiaochun Xu, Chief Executive Officer of Boyalife: Current Manufacturing Techniques are the Main Technical Barriers for the CAR-T Industry
In 2017, the first two commercial CAR-T therapies - Kymriah™ and Yescarta™ – received FDA approval. However, this does not [...]
BoyaLife Teams Up with China Science Daily and Cell Press to Promote Advancements in Stem Cell Research
On May 19, 2017, a forum on stem cell and regenerative medicine, entitled “Chinese Scientists and Cell Press,” jointly sponsored [...]
Bullish Capital! BoyaLife Increases Investment in US Subsidiary Cesca Therapeutics
On March 17, 2017, BoyaLife Group, through its wholy-owned investment fund, extended to its US subsidiary, Cesca Therapeutics, a 5-year, $5 [...]
First Boyalife, Science & Science Translational Medicine Award Ceremony Held in San Francisco
The first global awards ceremony for the Boyalife, Science & Science Translational Medicine Award in Stem Cells and Regenerative Medicine, [...]
Award honors Chinese-American for cellular science research
Qian Li, a 36-year-old Chinese-American scientist, recently took the top prize in the Boyalife, Science & Science Translational Medicine [...]
Boyalife Group investment hold the leader in the manufacture of automated blood and bone marrow processing systems
February 16, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL) , today reported financial results for the second quarter of [...]
Cesca Announces $15 Million Strategic Investment From Boyalife Group
Funds to be used to repay current senior secured convertible debentures and provide additional working capital to fund ongoing operations [...]
Boyalife and Science Magazine Jointly Launch A Global Award in Stem Cell and Regenerative Medicine
A piece of good news for young and middle-aged medical scientists around the globe! "Boyalife, Science & Science Translational [...]